多发性骨髓瘤中ABCB1/MDR1过表达导致卡非佐米耐药,奈非那韦和洛匹那韦可克服该耐药
该研究通过蛋白质组学分析发现,ABCB1过表达是卡非佐米耐药骨髓瘤细胞中最显著的变化,ABCB1过表达通过药物外排降低卡非佐米的蛋白酶体抑制活性。HIV蛋白酶抑制剂奈非那韦和洛匹那韦是ABCB1介导药物外排的有效功能调节剂,在治疗相关药物浓度下恢复卡非佐米活性,为临床试验中靶向ABCB1并使骨髓瘤细胞对卡非佐米等药物重新敏感提供了现成可用药物。
要点
- ABCB1过表达是卡非佐米耐药骨髓瘤细胞中最显著的蛋白质组学变化
- ABCB1过表达通过药物外排降低卡非佐米而非硼替佐米的蛋白酶体抑制活性
- 奈非那韦和洛匹那韦在治疗相关浓度下恢复卡非佐米活性
核心结论
- ABCB1过表达通过药物外排降低卡非佐米的蛋白酶体抑制活性,导致多发性骨髓瘤细胞对卡非佐米耐药。
- 奈非那韦和洛匹那韦是ABCB1介导药物外排的有效功能调节剂,可能通过调节线粒体通透性转换孔发挥作用。
- 奈非那韦和洛匹那韦在治疗相关药物浓度下恢复卡非佐米活性,是可供临床试验测试的现成药物,以靶向ABCB1并使骨髓瘤细胞对包括卡非佐米在内的已确立药物重新敏感。
研究设计与样本
- 研究采用蛋白质组学分析等方法,比较卡非佐米耐药与敏感骨髓瘤细胞,并评估ABCB1过表达的功能作用及HIV蛋白酶抑制剂奈非那韦和洛匹那韦对ABCB1介导药物外排的调节作用。
主要发现
- 蛋白质组学分析确定ABCB1过表达是卡非佐米耐药骨髓瘤细胞中最显著的变化。
- 外周血恶性浆细胞中ABCB1表达较未治疗患者骨髓浆细胞显著上调。
- ABCB1过表达通过药物外排降低卡非佐米的蛋白酶体抑制活性,而硼替佐米不受此影响。
- 在表达ABCB1的骨髓瘤细胞中,已确立抗骨髓瘤药物的细胞毒性显著降低。
- 奈非那韦和洛匹那韦是ABCB1介导药物外排的有效功能调节剂,最可能通过调节线粒体通透性转换孔发挥作用。
临床怎么用
- 原文结论指出奈非那韦和洛匹那韦是可供临床试验测试的现成药物,以靶向ABCB1并使浆细胞对已确立骨髓瘤药物(特别是卡非佐米)重新敏感。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Proteasome inhibitor (PI) carfilzomib (CFZ) has activity superior to bortezomib (BTZ) and is increasingly incorporated in multiple myeloma (MM) frontline therapy and relapsed settings. Most MM patients ultimately experience PI-refractory disease, an unmet medical need with poorly understood biology and dismal outcome. Pharmacologic targeting of ABCB1 improved patient outcomes, including MM, but suffered from adverse drug effects and insufficient plasma concentrations. Proteomics analysis identified ABCB1 overexpression as the most significant change in CFZ-resistant MM cells. We addressed the functional role of ABCB1 overexpression in MM and observed significantly upregulated ABCB1 in peripheral blood malignant plasma cells (PCs) vs untreated patients' bone marrow PC. ABCB1 overexpression reduces the proteasome-inhibiting activity of CFZ due to drug efflux, in contrast to BTZ. Likewise, the cytotoxicity of established anti-MM drugs was significantly reduced in ABCB1-expressing MM cells. In search for potential drugs targeting ABCB1 in clinical trials, we identified the HIV protease inhibitors nelfinavir (NFV) and lopinavir (LPV) as potent functional modulators of ABCB1-mediated drug export, most likely via modulation of mitochondria permeability transition pore. NFV and LPV restored CFZ activity at therapeutically relevant drug levels and thus represent ready-to-use drugs to be tested in clinical trials to target ABCB1 and to re-sensitize PC to established myeloma drugs, in particular CFZ.
引用
- Besse A, Stolze SC, Rasche L, et al. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. Leukemia. 2017. PMID: 28676669. doi:10.1038/leu.2017.212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。